Law360, New York (May 16, 2011, 2:20 PM ET) -- For the second time this year, Lupin Atlantis Holdings SA hauled Mylan Inc. into a Pennsylvania federal court on Thursday to block plans to manufacture a generic version of the cholesterol drug Antara.
Lupin Atlantis first sued Canonsburg, Pa.-based Mylan in March, alleging the generic-drug maker had infringed U.S. Patent Numbers 7,101,574 and 7,863,331. The patents, issued in September 2006 and this January, cover the composition and preparation of the drug, and methods of treatment using the drug, respectively.
The more recent suit also names Ethypharm...
Lupin Steps Up Fight With Mylan Over Generic Antara
To view the full article, take a free trial now.
